10450 Science Center Drive
San Diego, CA 92121
(858) 625 2424
5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560
Indicated for the intrathecal treatment of lymphomatous meningitis, DepoCyte(e)® has demonstrated improved response rates and a more convenient dosing regimen of cytarabine
The product's DepoFoam® formulation has extended the administration of cytarabine from twice weekly to once every two weeks.
DepoCyt® / DepoCyte® (cytarabine liposome injection) sustained-release administration allows for treatment to occur in an outpatient setting.
WARNING: DepoCyt(e)® (cytarabine liposome injection) should be administered only under the supervision of a qualified physician experienced in the use of intrathecal cancer chemotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available. In all clinical studies, chemical arachnoiditis, a syndrome manifested primarily by nausea, vomiting, headache and fever, was a common adverse event. If left untreated, chemical arachnoiditis may be fatal. The incidence and severity of chemical arachnoiditis can be reduced by coadministration of dexamethasone (see WARNINGS). Patients receiving DepoCyt(e)® should be treated concurrently with dexamethasone to mitigate the symptoms of chemical arachnoiditis (see DOSAGE AND ADMINISTRATION).
DEPOCYT HIGHLIGHT:
LYMPHOMATOUS MENINGITIS
Lymphomatous meningitis (LM) is cancer that started as primary lymphoma and has spread to the lining of the spinal cord and brain (this lining is the meninges). LM is reported in 5-15% of patients with diffuse high-grade non-Hodgkin’s lymphoma.
LM is rarely curable. However, research has shown that treatment that starts soon after the disease is detected can help many patients. In some patients, early treatment can prevent or slow worsening of symptoms caused by growth of cancer in the meninges.